We need your help now
Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
Sign in. It’s quick, free and it’s up to you.
An account is an optional way to support the work we do. Find out more.
By continuing, you are indicating that you accept our Terms of Service and Privacy Policy.
GENE THERAPY HAS been used to treat a person with haemophilia for the first time in Ireland, the Irish Haemophilia Society has announced today.
The person received the therapy as part of a clinical trial.
The society hailed it a major breakthrough and said it would have a major impact on the quality of life of people with the condition.
Haemophilia is a genetic condition where a person’s blood doesn’t clot properly, meaning they can bleed much more profusely.
Since the 1970s, the standard treatment for haemophilia has been regular injections of the missing clotting factor – usually managed by the patient themselves.
The new gene therapy helps the body independently produce the clotting factor, providing continuous bleed protection.
“This is a momentous occasion for the haemophilia community in Ireland”, Irish Haemophilia Society Chief Executive Brian O’Mahony said.
“In the past, viruses such as HIV and Hepatitis C decimated the haemophilia population in Ireland through contaminated blood.”
Dr Niamh O’Connell, National Director of the National Coagulation Centre at St. James’s Hospital, said:
Having your own liver producing a continuous level of factor is a real game-changer versus the treatments we currently have.
O’Mahony added: “In the coming years, you might start to see people actually being changed from having severe haemophilia into mild, or even normal factor levels. So it’s quite exciting.”
More trials are needed before the gene therapy becomes more widely used.
“There’s still lots to be learned. And I think the clinical trial setting is the way that we manage to get the benefits of new treatments in a safe environment, while gathering all of this information and data that helps us to improve the next round of studies,” Martina Hennessy, Director of the Health Research Board Clinical Research facility said.
There are a number of people enrolled for the current trial, and there are further trials about to open for other forms of haemophilia.
The trials were an academic collaboration between Trinity College and St James’s Hospital, and are funded by the Wellcome Trust in the UK and the Health Research Board in Ireland.
To embed this post, copy the code below on your site
Well fair play to the guards. Good work
And when he appears before Judge T O’Donnell it will all have been a complete waste of police time! He’ll be sentenced to 2 years’ jail, suspended for 2 years. Ridiculous but true.
@Richard Ahern: He has plenty form in that regard. A detached attitude to societal duty. Its not it his job description to declutter the prison system.
At least he wore a face mask.
have your say